Analyst Price Targets — PLSE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 10:42 am | — | Needham | $58.00 | $44.54 | TheFly | Pulse Biosciences initiated with a Buy at Needham |
| August 10, 2026 11:18 am | Anthony Petrone | Mizuho Securities | $45.00 | $42.41 | TheFly | Pulse Biosciences price target raised to $45 from $30 at Mizuho |
| August 10, 2026 11:00 am | William Plovanic | Canaccord Genuity | $43.00 | $42.41 | StreetInsider | Pulse Biosciences (PLSE) PT Raised to $43 at Canaccord |
| July 28, 2026 10:04 am | — | Oppenheimer | $35.00 | $32.79 | StreetInsider | Pulse Biosciences (PLSE) PT Raised to $35 at OppenheimerMember Login |
| June 4, 2026 10:22 am | — | Canaccord Genuity | $32.00 | $24.99 | TheFly | Pulse Biosciences initiated with a Buy at Canaccord |
| February 20, 2026 1:08 pm | Suraj Kalia | Oppenheimer | $30.00 | $22.03 | TheFly | Pulse Biosciences price target raised to $30 from $22 at Oppenheimer |
| February 6, 2026 12:39 pm | — | Mizuho Securities | $30.00 | $13.69 | TheFly | Pulse Biosciences price target raised to $30 from $25 at Mizuho |
| January 30, 2026 10:13 am | — | Mizuho Securities | $25.00 | $13.62 | TheFly | Pulse Biosciences initiated with an Outperform at Mizuho |
Latest News for PLSE
Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 866,061 shares of the company's stock after buying an additional 65,884 shares
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The stock traded as high as $48.10 and last traded at $46.00, with a volume of 525728 shares trading hands. The stock had previously closed at $46.79. Analyst Upgrades and Downgrades PLSE has been the subject
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the…
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PLSE.
U.S. House Trading
No House trades found for PLSE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.